Arunee Dechaphunkul

8.5k total citations · 1 hit paper
62 papers, 855 citations indexed

About

Arunee Dechaphunkul is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Arunee Dechaphunkul has authored 62 papers receiving a total of 855 indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Pulmonary and Respiratory Medicine, 32 papers in Oncology and 19 papers in Surgery. Recurrent topics in Arunee Dechaphunkul's work include Lung Cancer Treatments and Mutations (19 papers), Head and Neck Cancer Studies (13 papers) and Gastric Cancer Management and Outcomes (9 papers). Arunee Dechaphunkul is often cited by papers focused on Lung Cancer Treatments and Mutations (19 papers), Head and Neck Cancer Studies (13 papers) and Gastric Cancer Management and Outcomes (9 papers). Arunee Dechaphunkul collaborates with scholars based in Thailand, China and Canada. Arunee Dechaphunkul's co-authors include Shun Lü, Yuri Rukazenkov, Ki Hyeong Lee, Wu‐Chou Su, Yi‐Long Wu, Margarita Majem, Christian Grohé, Filippo de Marinis, Frances A. Shepherd and Masahiro Tsuboi and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Arunee Dechaphunkul

55 papers receiving 837 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Overall Survival with Osimertinib in Resected EGFR -Mutated NSCLC

2023 263 citations Shun Lü, Arunee Dechaphunkul et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Arunee Dechaphunkul Thailand	13	520	468	190	156	152	62	855
Naoko Miura Japan	17	514 1.0×	459 1.0×	224 1.2×	125 0.8×	123 0.8×	62	919
Ryo Toyozawa Japan	17	629 1.2×	618 1.3×	182 1.0×	105 0.7×	66 0.4×	89	932
Juliette Haudebourg France	14	268 0.5×	206 0.4×	144 0.8×	119 0.8×	208 1.4×	37	651
Hironaga Satake Japan	18	573 1.1×	667 1.4×	97 0.5×	156 1.0×	372 2.4×	147	1.1k
Virginia Arrazubi Spain	12	235 0.5×	372 0.8×	136 0.7×	109 0.7×	155 1.0×	48	641
Yongbin Lin China	21	658 1.3×	714 1.5×	136 0.7×	144 0.9×	306 2.0×	63	1.2k
Yukiko Niwa Japan	20	380 0.7×	402 0.9×	223 1.2×	134 0.9×	405 2.7×	41	913
Chihiro Kondoh Japan	13	241 0.5×	302 0.6×	109 0.6×	72 0.5×	160 1.1×	49	546
Keita Kudo Japan	13	611 1.2×	1.0k 2.2×	173 0.9×	107 0.7×	122 0.8×	35	1.3k
Xiaobo He China	7	215 0.4×	412 0.9×	79 0.4×	166 1.1×	81 0.5×	8	561

Countries citing papers authored by Arunee Dechaphunkul

Since Specialization

Citations

This map shows the geographic impact of Arunee Dechaphunkul's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Arunee Dechaphunkul with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Arunee Dechaphunkul more than expected).

Fields of papers citing papers by Arunee Dechaphunkul

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Arunee Dechaphunkul. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Arunee Dechaphunkul. The network helps show where Arunee Dechaphunkul may publish in the future.

Co-authorship network of co-authors of Arunee Dechaphunkul

This figure shows the co-authorship network connecting the top 25 collaborators of Arunee Dechaphunkul. A scholar is included among the top collaborators of Arunee Dechaphunkul based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Arunee Dechaphunkul. Arunee Dechaphunkul is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sunpaweravong, Patrapim, et al.. (2025). A 20-Year Real-World Study of Small Bowel Cancers: Histologic Subtypes, Clinical Features, and Survival Implications. Journal of Clinical Medicine. 14(19). 6962–6962. 1 indexed citations

Dechaphunkul, Arunee, et al.. (2025). Clinical Outcomes of HER2‐Low Versus HER2‐Zero in HR‐Positive Metastatic Breast Cancer Treated With Endocrine Therapy With or Without CDK4/6 Inhibitors: A Multicenter Retrospective Study. International Journal of Breast Cancer. 2025(1). 5597051–5597051.

Wetwittayakhlang, Panu, et al.. (2025). Association Between Epstein–Barr Virus Infection and PD-L1 Expression in Gastric Cancer: Prevalence, Clinicopathological Features, and Prognostic Implications. Cancers. 17(9). 1492–1492. 2 indexed citations

Psyrri, Amanda, Christophe Le Tourneau, Arunee Dechaphunkul, et al.. (2025). 1348MO SKYSCRAPER-09: Phase II, randomised study of tiragolumab (tira) + atezolizumab (atezo) and atezo + placebo (pbo) as first-line (1L) treatment in patients (pts) with recurrent/metastatic PD-L1+ squamous cell carcinoma of the head and neck (R/M SCCHN). Annals of Oncology. 36. S776–S777.

Wetwittayakhlang, Panu, et al.. (2024). Comparing the Efficacy of Carboplatin plus 5-Fluorouracil, Cisplatin plus 5-Fluorouracil, and Best Supportive Care for Advanced Esophageal Squamous Cell Carcinoma: A Propensity Score Analysis from a Tertiary Hospital in Southern Thailand. Journal of Clinical Medicine. 13(6). 1735–1735. 2 indexed citations

Ithimakin, Suthinee, et al.. (2024). Comparative effectiveness analysis of survival with first-line palbociclib or ribociclib plus AI in HR + /HER2- advanced breast cancer (CEPRA study): preliminary analysis of real-world data from Thailand. BMC Cancer. 24(1). 1018–1018. 4 indexed citations

Wetwittayakhlang, Panu, et al.. (2024). Comparative Analysis of Concurrent Chemoradiotherapy Versus Chemotherapy Alone as First-Line Palliative Treatments for Advanced Esophageal Squamous Cell Carcinoma. Journal of Clinical Medicine. 13(21). 6353–6353.

Ngamphaiboon, Nuttapong, Arunee Dechaphunkul, Chanida Vinayanuwattikun, et al.. (2023). 891P Changing landscape of head and neck squamous cell carcinoma (HNSCC) treatment and survival in Thailand: A 13-year multicenter retrospective study of 6,319 patients. Annals of Oncology. 34. S570–S570.

Tanomkiat, Wiwatana, Pisud Siripaitoon, Nawamin Pinpathomrat, et al.. (2023). Characteristics, Outcomes, and Factors Affecting Mortality in Hospitalized Patients with CAP Due to Different Variants of SARS-CoV-2 and Non-COVID-19 CAP. Journal of Clinical Medicine. 12(4). 1388–1388. 1 indexed citations

10.

Geater, Sarayut Lucien, et al.. (2021). Benefits of immunonutrition in patients with head and neck cancer receiving chemoradiation: A phase II randomized, double-blind study. Clinical Nutrition. 41(2). 433–440. 21 indexed citations

11.

Clingan, P., Daniel Brungs, Rahul Ladwa, et al.. (2020). 1084P Cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma (mCSCC): Preliminary safety and efficacy results from a phase I clinical trial. Annals of Oncology. 31. S736–S736. 6 indexed citations

12.

Sripongpun, Pimsiri, et al.. (2019). Hepatitis B screening rates and reactivation in solid organ malignancy patients undergoing chemotherapy in Southern Thailand. Clinical and Molecular Hepatology. 25(4). 366–373. 4 indexed citations

13.

Planchard, David, Michael Boyer, Arunee Dechaphunkul, et al.. (2018). Osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with untreated EGFRm advanced NSCLC: FLAURA post-progression outcomes. Annals of Oncology. 29. ix150–ix150. 2 indexed citations

14.

Planchard, David, Michael Boyer, Jin Sun Lee, et al.. (2018). 128O Osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with untreated EGFRm advanced NSCLC: FLAURA post-progression outcomes. Journal of Thoracic Oncology. 13(4). S72–S73. 13 indexed citations

15.

Zhang, L., Shun Lü, J. Feng, et al.. (2017). A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC). Annals of Oncology. 29(2). 452–458. 66 indexed citations

16.

Cho, Byoung Chul, K.H. Lee, Arunee Dechaphunkul, et al.. (2017). Osimertinib vs standard of care (SoC) EGFR-TKI as first-line treatment in patients with EGFR-TKI sensitising mutation (EGFRm) positive advanced non-small cell lung cancer (NSCLC): FLAURA Asian subset. Annals of Oncology. 28. x190–x190. 2 indexed citations

17.

Ramalingam, Sundar, Thanyanan Reungwetwattana, Arunee Dechaphunkul, et al.. (2017). Osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFRm advanced NSCLC: FLAURA. Annals of Oncology. 28. v635–v635. 20 indexed citations

18.

Ohe, Yuichiro, Suresh S. Ramalingam, Thanyanan Reungwetwattana, et al.. (2017). Osimertinib vs standard of care EGFR-TKI as first-line treatment in patients with EGFRm advanced NSCLC: FLAURA. Annals of Oncology. 28. x125–x125. 1 indexed citations

19.

Dechaphunkul, Arunee, et al.. (2012). Prognostic Significance of Tissue Inhibitor of Metalloproteinase-1 in Breast Cancer. International Journal of Breast Cancer. 2012. 1–10. 36 indexed citations

20.

Dechaphunkul, Arunee, et al.. (2011). Antihormonal Therapy in Breast Cancer. SHILAP Revista de lepidopterología.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact